Dimensional Fund Advisors LP Acquires Shares of 16,412 Mineralys Therapeutics, Inc. (NASDAQ:MLYS)

Dimensional Fund Advisors LP acquired a new stake in Mineralys Therapeutics, Inc. (NASDAQ:MLYS) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 16,412 shares of the company’s stock, valued at approximately $202,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Jennison Associates LLC grew its holdings in Mineralys Therapeutics by 55.4% in the 4th quarter. Jennison Associates LLC now owns 1,082,006 shares of the company’s stock valued at $13,319,000 after buying an additional 385,726 shares in the last quarter. Barclays PLC grew its holdings in shares of Mineralys Therapeutics by 281.8% during the 3rd quarter. Barclays PLC now owns 38,218 shares of the company’s stock worth $463,000 after purchasing an additional 28,208 shares in the last quarter. Wellington Management Group LLP grew its holdings in shares of Mineralys Therapeutics by 43.0% during the 4th quarter. Wellington Management Group LLP now owns 91,529 shares of the company’s stock worth $1,127,000 after purchasing an additional 27,531 shares in the last quarter. Proficio Capital Partners LLC acquired a new stake in shares of Mineralys Therapeutics during the 4th quarter worth $285,000. Finally, Charles Schwab Investment Management Inc. grew its holdings in shares of Mineralys Therapeutics by 0.6% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 214,906 shares of the company’s stock worth $2,645,000 after purchasing an additional 1,307 shares in the last quarter. 84.46% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Mineralys Therapeutics

In other Mineralys Therapeutics news, Director Ra Capital Management, L.P. acquired 1,296,296 shares of Mineralys Therapeutics stock in a transaction that occurred on Thursday, March 13th. The shares were acquired at an average cost of $13.50 per share, with a total value of $17,499,996.00. Following the completion of the purchase, the director now directly owns 4,280,051 shares of the company’s stock, valued at $57,780,688.50. This represents a 43.45% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Jon Congleton sold 15,319 shares of Mineralys Therapeutics stock in a transaction dated Friday, April 11th. The shares were sold at an average price of $12.19, for a total value of $186,738.61. Following the sale, the chief executive officer now directly owns 862,289 shares in the company, valued at $10,511,302.91. The trade was a 1.75% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 104,579 shares of company stock valued at $1,534,353 over the last ninety days. 25.56% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on MLYS. HC Wainwright reissued a “buy” rating and set a $42.00 target price on shares of Mineralys Therapeutics in a report on Tuesday, May 13th. Guggenheim reissued a “buy” rating on shares of Mineralys Therapeutics in a report on Monday, February 24th. Finally, The Goldman Sachs Group reduced their target price on Mineralys Therapeutics from $28.00 to $24.00 and set a “buy” rating on the stock in a report on Thursday, February 13th.

Mineralys Therapeutics Stock Down 0.1%

NASDAQ:MLYS opened at $15.35 on Friday. The stock’s 50-day simple moving average is $14.29 and its 200 day simple moving average is $12.47. The firm has a market capitalization of $995.85 million, a PE ratio of -4.22 and a beta of -0.30. Mineralys Therapeutics, Inc. has a twelve month low of $8.24 and a twelve month high of $18.38.

Mineralys Therapeutics (NASDAQ:MLYS) last released its quarterly earnings data on Monday, May 12th. The company reported ($0.79) earnings per share for the quarter, beating the consensus estimate of ($1.02) by $0.23. On average, analysts anticipate that Mineralys Therapeutics, Inc. will post -4.23 EPS for the current fiscal year.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.